Trial Profile
Neoadjuvant Phase II Trial of Paclitaxel in Combination With BKM120 in Endocrine Resistant Clinical Stage II or III Estrogen Receptor-Positive and HER2 Negative Breast Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Buparlisib (Primary) ; Paclitaxel
- Indications Breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- 24 Nov 2014 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 03 Sep 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 03 May 2014 Planned initiation date changed from 1 Jan 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov record.